FOR IMMEDIATE RELEASE

Caris Life Sciences to Present Key Research Findings on its Molecular Intelligence Platform at the 2017 ASCO Annual Meeting

Presentations Demonstrate Utility of Tumor Profiling to Guide Individualized Treatment

IRVING, Tex., May 24, 2017 – Caris Life Sciences®, a leading innovator in molecular science focused on fulfilling the promise of precision medicine, today announced the acceptance of 11 abstracts, including an oral abstract session, two poster discussion sessions and eight poster sessions, by the American Society of Clinical Oncology (ASCO) for presentation at its annual meeting, being held June 2-5, 2017 in Chicago. The studies were conducted in collaboration with industry-leading academic and clinical institutions employing the company’s proprietary Caris Molecular Intelligence® Comprehensive Genomic Profiling Plus (CGP+) tumor profiling platform. Caris Molecular Intelligence identifies molecular aberrations which aid clinicians in delivering the most optimal and personalized treatment plan for each patient.

David Spetzler, MS, PhD, MBA, President and Chief Scientific Officer of Caris, commented, “Our Comprehensive Genomic Profiling Plus approach to tumor profiling provides a unique opportunity to decode cancer and guide more precise and personalized treatment decisions. Our platform helps both clinicians and biopharmaceutical companies better understand cancer biology and ultimately increase the chances for successful outcomes for each cancer patient. We are excited to be presenting a multitude of supporting data during this year’s ASCO.”

Oral Abstract Session

- Monday, June 5, 8:24 – 8:36 a.m. CT, S404

Poster Discussion Sessions

- Saturday, June 3, 4:45 – 6:00 p.m. CT, S406
  Poster Discussion Session: Tumor Biology “Characterization of tumor mutation load (TML) in solid tumors” presented by Mohamed Salem, MD, MedStar Georgetown Lombardi, University of Southern California, Karmanos Cancer Institute, Levine Cancer Institute, Fox Chase Cancer Center, Abstract 11517, Poster 217.
• Monday, June 5, 4:45 – 6:00 p.m. CT, S404
Poster Discussion Session: Brain Cancer “**RNASeq analysis of glioma tumors reveal targetable gene fusions**” presented by Deepa S. Subramaniam, MD, MedStar Georgetown Lombardi, Barrow Neurological Institute, MD Anderson Cancer Center, Abstract 2019, Poster 261.

**Poster Sessions:**

• Saturday, June 3, 8:00 – 11:30 a.m. CT, Hall A
Poster Session: Tumor Biology “**Impact of primary tumor location on genetic alterations**” presented by Mohamed E. Salem, MD, MedStar Georgetown Lombardi, University of Southern California, Karmanos Cancer Institute, Levine Cancer Institute, Abstract 3578, Poster 201.

• Saturday, June 3, 8:00 – 11:30 a.m. CT, Hall A

• Saturday, June 3, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Breast Cancer “**Molecular profiling comparison of breast cancer subtypes in young women and older women**” presented by Antionette R. Tan, MD, Levine Cancer Institute, Abstract 11581, Poster 281.

• Saturday, June 3, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Gastrointestinal (Colorectal) and Uterine Cancers “**Variable DNA mismatch repair associated gene profiles in colorectal versus uterine cancers**” presented by Tabari Baker, PhD, Fox Chase Cancer Center, Ohio State University, Abstract 11610, Poster 310.

• Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Breast Cancer “**Distribution of receptor tyrosine kinase (RTK) nsSNPs in breast cancer (BC) patients (pts) using Next-Generation Sequencing (NGS)**” presented by Lindsay Morris, MD, West Cancer Center, Abstract 1080, Poster 72.

• Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Tumor Biology “**Potential therapeutic genomic alterations in desmoplastic small round blue cell tumor**” presented by Joanne Xiu, PhD, Kymera Independent Physicians, All Saints University, Abstract 1066, Poster 389.

• Sunday, June 4, 8:00 – 11:30 a.m. CT, Hall A
Poster session: Genitourinary Cancer “**Spectrum of tumor mutational load (TML) in genitourinary (GU) cancers**” presented by Muhammed Azam Hussain, MD, Penn State University, Karmanos Cancer Institute, Abstract 4535, Poster 213.
Monday, June 5, 1:15 – 4:45 p.m. CT, Hall A
Poster session: Tumor Biology “Localization of non-receptor tyrosine kinase (nRTK) variants identified in solid tumor patients with Next-Generation Sequencing (NGS)” presented by Srishti Sareen, MD, West Cancer Center, Abstract 1536, Poster 194.

About Caris Life Sciences
Caris Life Sciences® is a leading innovator in molecular science focused on fulfilling the promise of precision medicine through quality and innovation. Caris Molecular Intelligence®, the company’s Comprehensive Genomic Profiling Plus (CGP+) molecular testing service and the world’s leading immunotherapy diagnostic expert, assesses DNA, RNA and proteins, including microsatellite instability (MSI), total mutational load (TML) and PD-L1, to reveal the molecular drivers of cancer and enable the delivery of personalized medicine. The ADAPT Biotargeting System®, the company’s revolutionary and unbiased profiling platform, is currently being utilized for drug target identification, therapeutic discovery and development, fixed tissue-based companion diagnostics, blood-based cancer screening and biomarker identification. Headquartered in Irving, Texas, Caris Life Sciences offers services throughout the U.S., Europe and other international markets. To learn more, please visit www.CarisLifeSciences.com.

# # #

Media Inquiries:
The Ruth Group
Kirsten Thomas / Joanna Zimmerman
kthomas@theruthgroup.com / jzimmerman@theruthgroup.com
Tel: +1-508-280-6592 / +1-646-536-7006
Source: Caris Life Sciences

Caris Life Sciences Media Relations & Corporate Affairs
CorpComm@carisls.com
214-294-5606